Autoantibodies Are Early Diabetes Warning Signs
|
By LabMedica International staff writers Posted on 09 Mar 2015 |
Detection of autoantibodies directed against pancreatic islet cells can be used to predict the likelihood of a child developing type I diabetes.
Investigators at Lund University (Sweden) recruited 8,503 participants in the TEDDY (The Environmental Determinants of Diabetes in the Young) study to take part in their autoantibody experiment. The TEDDY study, funded by the [US] National Institutes of Health, involved 8,600 children from Sweden, the USA, Finland, and Germany, who showed an increased hereditary risk of type I diabetes, detected at birth through tests on umbilical cord blood.
Infants with HLA-DR high-risk genotypes (DR3/4, DR4/4, DR4/8, and DR3/3) from the TEDDY group were prospectively followed with standardized autoantibody assessments quarterly throughout the first four years of life and then semiannually thereafter. The Lund University researchers reported that 6.5% of the participating children had their first autoantibody before the age of six. In 44% of cases, they only had an autoantibody against insulin (IAA). Most of them had this by the age of one to two years. In 38% of cases, GAD65 autoantibodies (GADA) were detected. The numbers increased until the age of two and then remained constant. In 14% of cases both autoantibodies were found at the same time, with a peak at the age of two to three.
The investigators concluded from the results that there were three ways to predict development of type I diabetes: 1) if the autoantibody first discovered attacked insulin (IAA); 2) if the first autoantibody targeted GAD65 (GADA), a protein inside the insulin-producing cells; or 3) if both autoantibodies were first found together.
"In the TEDDY study we have found that autoantibodies often appear during the first few years of life", said contributing author Dr. Åke Lernmark, professor of experimental diabetes at Lund University. "If a second autoantibody is detected later, then the person will get diabetes - but it may take up to 20 years. In TEDDY, 40% of these children had already developed diabetes. It is possible that there are two different diseases involved. Perhaps one virus triggers the autoantibodies against insulin and another one the autoantibodies against GAD65."
The study was published in the February 10, 2015, online edition of the journal Diabetologia.
Related Links:
Lund University
Investigators at Lund University (Sweden) recruited 8,503 participants in the TEDDY (The Environmental Determinants of Diabetes in the Young) study to take part in their autoantibody experiment. The TEDDY study, funded by the [US] National Institutes of Health, involved 8,600 children from Sweden, the USA, Finland, and Germany, who showed an increased hereditary risk of type I diabetes, detected at birth through tests on umbilical cord blood.
Infants with HLA-DR high-risk genotypes (DR3/4, DR4/4, DR4/8, and DR3/3) from the TEDDY group were prospectively followed with standardized autoantibody assessments quarterly throughout the first four years of life and then semiannually thereafter. The Lund University researchers reported that 6.5% of the participating children had their first autoantibody before the age of six. In 44% of cases, they only had an autoantibody against insulin (IAA). Most of them had this by the age of one to two years. In 38% of cases, GAD65 autoantibodies (GADA) were detected. The numbers increased until the age of two and then remained constant. In 14% of cases both autoantibodies were found at the same time, with a peak at the age of two to three.
The investigators concluded from the results that there were three ways to predict development of type I diabetes: 1) if the autoantibody first discovered attacked insulin (IAA); 2) if the first autoantibody targeted GAD65 (GADA), a protein inside the insulin-producing cells; or 3) if both autoantibodies were first found together.
"In the TEDDY study we have found that autoantibodies often appear during the first few years of life", said contributing author Dr. Åke Lernmark, professor of experimental diabetes at Lund University. "If a second autoantibody is detected later, then the person will get diabetes - but it may take up to 20 years. In TEDDY, 40% of these children had already developed diabetes. It is possible that there are two different diseases involved. Perhaps one virus triggers the autoantibodies against insulin and another one the autoantibodies against GAD65."
The study was published in the February 10, 2015, online edition of the journal Diabetologia.
Related Links:
Lund University
Latest Clinical Chem. News
- Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
- Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
- Blood Antibody Linked to Lower Depression and PTSD Symptoms After Brain Injury
- Blood Biomarker May Help Monitor Early Response to Lecanemab in Alzheimer’s Disease
- New Reference Material Aims to Improve Comparability of Angiotensin II Testing
- Childhood Blood Biomarkers May Reveal Early Heart, Kidney, and Metabolic Risks
- Blood Biomarker Study Reveals Early Signals of Future Cognitive Difficulties
- International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes
- Electrical Fingerprint of Extracellular Vesicles Could Detect Pancreatic Cancer
- Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening
- Blood Biomarker May Track Bone Metastases in Medullary Thyroid Cancer
- Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy
- New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction
- Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
- New Biomarker Recommendations Aim to Personalize Stroke Rehabilitation
- Validated Biomarker Blood Test Detects Early Lung Cancer and Supports Risk Assessment
Channels
Molecular Diagnostics
view channel
Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples
Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more
FDA Clears Compact Molecular COVID Test for Decentralized Care Settings
Decentralized healthcare settings such as urgent care clinics have historically struggled to deploy high-performance molecular testing. Barriers include high upfront costs, fixed testing capacity, large... Read moreHematology
view channel
New Automated Hemostasis Systems Become Available Across US Laboratories
Hemostasis testing supports critical decisions in surgery, anticoagulation management, and the evaluation of bleeding and thrombotic disorders, but laboratories continue to face rising volumes and complex... Read more
Variation in AML Residual Disease Testing Prompts Push for Standardization
Acute myeloid leukemia (AML) is an aggressive blood cancer in which relapse after therapy remains a persistent challenge, making measurable residual disease (MRD) detection central to risk assessment and... Read moreImmunology
view channel
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channelMagnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more
Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
Eczema, or atopic dermatitis, and food allergies often begin in infancy and are among the earliest stages of the atopic march. Atopic dermatitis alone can affect up to 20% of children, yet objective indicators... Read more
Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. Misordered or overused assays can complicate infection metrics, trigger penalties, and strain... Read more
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read morePathology
view channel
Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more
CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing
Standardized biomarker reporting and molecular profiling are central to pathology-driven cancer care, but evolving practices require laboratories to keep reporting templates current. These templates capture... Read moreTechnology
view channel
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Unilabs Expands Digital Pathology Across European Network with Proscia Platform
As precision medicine expands, digital pathology platforms must connect teams, sites, diagnostic data, and artificial intelligence to accelerate routine diagnosis. Sharing expertise across laboratory networks... Read more
MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026
MGI Tech Co., Ltd. (Shenzhen, China) introduced VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence staining and imaging system, at the 38th European Congress of Pathology (ECP 2026)... Read more







